A new player in MHC class I processing and presentation. (360G-Wellcome-085038_Z_08_Z)
Peptide loading of Major Histocompatibility Complex (MHC) class I molecules is essential for their function in the immune system. I have recently identified a novel molecule, named TAPBPR, can inhibit this process. In cells expressing TAPBPR, the expression of conventionally folded MHC class I heterotrimers is decreased. In their place, unconventional forms of MHC class I molecules are displayed. Such alterations to MHC class I surface expression is likely to have a significant impact on immu nological recognition and consequential influences on immune responses. Thus, it is essential to further understand the role of this novel molecule, TAPBPR, in the context of human Immunology. This project aims to elucidate the immunological function of TAPBPR in MHC class I processing and presentation. Two key areas in which TAPBPR expression, and its consequential affects on MHC class I expression, will be explored: 1) The role of TAPBPR in cellular stress 2) The role of TAPBPR in cro ss-presentation in Dendritic cells Ultimately, this project aims to elucidate the role of TAPBPR and its contribution to human health and disease.
£493,514 09 Dec 2008